FDA Expands Talzenna Plus Xtandi Approval to Earlier Prostate Cancer Stage

what happened

The US Food and Drug Administration (FDA) has widened its approval of Talzenna (talazoparib) used together with Xtandi (enzalutamide). The combination is now cleared for men with metastatic hormone-sensitive prostate cancer carrying HRR gene mutations, including both BRCA and non-BRCA mutations. Pfizer announced the decision, and Reuters and TradingView also reported it.

The approval was based on the Phase 3 TALAPRO-3 study. The combination cut the risk of radiographic progression or death by 52% versus placebo plus Xtandi (hazard ratio 0.48). About 77% of patients remained progression-free at three years. The most common grade 3 or higher adverse event was anemia, reported by 51% of patients in the combination group and 3% in the control group.

why it matters

For Pfizer, this is a meaningful expansion into an earlier segment of the oncology market. Astellas, which co-commercializes Xtandi in the United States, also has a commercial stake. An application is still under review at the European Medicines Agency, so further regulatory decisions could shape sales momentum.

market impact

Pfizer and Astellas: wider approval enlarges the potential sales base for both drugs

tags

instruments